AVITA Medical

AVITA Medical is a commercial-stage therapeutic acute wound care company whose RECELL System harvests and sprays a patient's own skin cells to treat thermal burn wounds and full-thickness skin defects, with an expanding label into repigmentation of stable vitiligo lesions. The device family includes RECELL GO (line extensions for wounds up to 1,920 cm²) plus distributed biologics PermeaDerm and Cohealyx. The company is dual-listed on Nasdaq (RCEL) and the ASX (AVH), operates in the US, Japan, the EU, Australia, and the UK, and raised its 2026 revenue guidance in August 2026 while guiding to fourth-quarter cash-flow breakeven.